Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee.
Twelves CJ, Gardner C, Flavin A, Sludden J, Dennis I, de Bono J, Beale P, Vasey P, Hutchison C, Macham MA, Rodriguez A, Judson I, Bleehen NM.
Twelves CJ, et al. Among authors: beale p.
Br J Cancer. 1999 Aug;80(11):1786-91. doi: 10.1038/sj.bjc.6690598.
Br J Cancer. 1999.
PMID: 10468297
Free PMC article.
Clinical Trial.